Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain

References

• Gan TJ, Epstein RS, Leone-Perkins ML, et al. Practice patterns and treatment challenges in acute postoperative pain management: a survey of practicing physicians. Pain Ther. 2018 Dec;7(2):205–216.
   PubMed Web of Science ®Google Scholar
• Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287–2298.
   PubMed Web of Science ®Google Scholar
• Stephens J, Laskin B, Pashos C, et al. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford). 2003 Nov;42(Suppl 3):iii40–52.
   PubMedGoogle Scholar
• Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, executive committee, and administrative council. J Pain. 2016 Feb;17(2):131–157.
   PubMed Web of Science ®Google Scholar
• Shafi S, Collinsworth AW, Copeland LA, et al. Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system. JAMA Surg. 2018 Aug 1;153(8):757–763.
   PubMed Web of Science ®Google Scholar
• Gonzales J, Lovald ST, Lau EC, et al. Risk of opioid-related adverse events after primary and revision total knee arthroplasty. J Surg Orthop Adv. 2018;27(2):148–154.
   PubMedGoogle Scholar
• Wheeler M, Oderda GM, Ashburn MA, et al. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002 Jun;3(3):159–180.
   PubMed Web of Science ®Google Scholar
• Jalal H, Buchanich JM, Roberts MS, et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018 Sep 21;361:6408.
   Web of Science ®Google Scholar
• Bedene A, Lijfering WM, Niesters M, et al. Opioid prescription patterns and risk factors associated with opioid use in the Netherlands. JAMA Network Open. 2019 Aug 2;2(8):e1910223.
   PubMed Web of Science ®Google Scholar
• Gupta K, Nagappa M, Prasad A, et al. Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses. BMJ Open. 2018 Dec 14;8(12):e024086.
   PubMed Web of Science ®Google Scholar
• Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth. 2004 Aug;93(2):212–223.
   PubMed Web of Science ®Google Scholar
• Macintyre PE, Loadsman JA, Scott DA. Opioids, ventilation and acute pain management. Anaesth Intensive Care. 2011 Jul;39(4):545–558.
   PubMed Web of Science ®Google Scholar
• Kessler ER, Shah M, Gruschkus SK, et al. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013 Apr;33(4):383–391.
   PubMed Web of Science ®Google Scholar
• Koepke EJ, Manning EL, Miller TE, et al. The rising tide of opioid use and abuse: the role of the anesthesiologist. Perioper Med (Lond). 2018;7:16.
   PubMedGoogle Scholar
• Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011 Apr;12(4):657–667.
   PubMed Web of Science ®Google Scholar
• Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016 Oct;54(10):901–906.
   PubMed Web of Science ®Google Scholar
• Soergel DG, Subach RA, Burnham N, et al. Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 2014 Sep;155(9):1829–1835.
   PubMed Web of Science ®Google Scholar
• Ehrlich AT, Kieffer BL, Darcq E. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin Ther Targets. 2019 Apr;23(4):315–326.
   PubMed Web of Science ®Google Scholar
• Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005 Sep;314(3):1195–1201.
   PubMed Web of Science ®Google Scholar
• DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708–717.
   PubMed Web of Science ®Google Scholar
• Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci. 2007 Aug;28(8):416–422.
   PubMed Web of Science ®Google Scholar
• Siuda ER, Carr R 3rd, Rominger DH, et al. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol. 2017;32:77–84.
   PubMed Web of Science ®Google Scholar
• Kliewer A, Schmiedel F, Sianati S, et al. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019;10(1):1–11.
   PubMedGoogle Scholar
• Gillis A, Gondin AB, Kliewer A, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 2020;13:625.
   Web of Science ®Google Scholar
• Food and Drug Administration. Highlights of prescribing information: olinvyk (oliceridine) 2020 [cited 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210730s001lbl.pdf
   Google Scholar
• Trevena. Olinvyk prescribing information [cited 2020]. Available from: https://olinvyk.com
   Google Scholar
• Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016 Jan;157(1):264–272.
   PubMed Web of Science ®Google Scholar
• Liang DY, Li WW, Nwaneshiudu C, et al. Pharmacological characters of oliceridine, a mu-opioid receptor G-protein-biased ligand in mice. Anesth Analg. 2019 Nov;129(5):1414–1421.
   PubMed Web of Science ®Google Scholar
• Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017;10:2413–2424.
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–943.
   PubMed Web of Science ®Google Scholar
• Singla NK, Skobieranda F, Soergel DG, et al. APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019 Sep;19(7):715–731.
   PubMed Web of Science ®Google Scholar
• Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), A G-protein selective agonist at the micro-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J Pain Res. 2019;12:3113–3126.
   PubMed Web of Science ®Google Scholar
• Weil JV, McCullough RE, Kline JS, et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med. 1975 May 22;292(21):1103–1106.
   PubMed Web of Science ®Google Scholar
• Ayad S, Demitrack MA, Burt DA, et al. Evaluating the incidence of opioid-induced respiratory depression associated with oliceridine and morphine as measured by the frequency and average cumulative duration of dosing interruption in patients treated for acute postoperative pain. Clin Drug Investig. 2020 Aug;40(8):755–764.
   PubMed Web of Science ®Google Scholar
• Dahan A, Van Dam CJ, Niesters M, et al. Benefit and risk evaluation of biased mu-receptor agonist oliceridine versus morphine. Anesthesiology. 2020 Sep 1;133(3):559–568.
   PubMed Web of Science ®Google Scholar
• Bergese S, Berkowitz R, Rider P, et al. Low incidence of postoperative respiratory depression with oliceridine compared to morphine: a retrospective chart analysis. Pain Res Manag. 2020;2020:7492865.
   PubMed Web of Science ®Google Scholar
• Brzezinski M, Hammer GB, Candiotti KA, et al. Low incidence of opioid-induced respiratory depression observed with oliceridine regardless of age or body mass index. Pain Ther. 2020;10:457-473.
   Web of Science ®Google Scholar
• Beard TL, Michalsky C, Candiotti KA, et al. Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 2020 Nov 18;10:401-413.
   PubMed Web of Science ®Google Scholar
• Altarifi AA, David B, Muchhala KH, et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017 Jun;31(6):730–739.
   PubMed Web of Science ®Google Scholar
• Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S55–72.
   PubMed Web of Science ®Google Scholar
• Austin Zamarripa C, Edwards SR, Qureshi HN, et al. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend. 2018 Nov 1;192:158–162.
   PubMed Web of Science ®Google Scholar
• Nafziger AN, Arscott KA, Cochrane K, et al. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine. Clin Pharmacol Drug Dev. 2020;9(5):639–650.
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006 Feb;11(2):126–135.
   PubMed Web of Science ®Google Scholar